Monopar Therapeutics Inc. · NASDAQ:MNPR

Monopar Therapeutics — Investor Presentation (November 2026)

38 slides from Monopar Therapeutics's investor presentation, November 2026

  1. Slide 1: Monopar Therapeutics Inc.

    Monopar Therapeutics Inc. Nasdaq: MNPR November 2026 ©2026 Monopar

  2. Slide 2: Disclaimer, Forward-Looking Statements

    DISCLAIMER, FORWARD-LOOKING STATEMENTS This presentation does not and shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any offer, solicitation or sale of the securities in any state or jurisdiction in which such offer, solicitation or sa

  3. Slide 3: Monopar: Advancing Targeted Therapies for Wilson Disease and Cancer

    Monopar: A Biopharmaceutical Company Advancing Next Generation Targeted Therapies for Wilson Disease and Cancer ALXN1840 Bringing innovation to areas a novel mechanism, first-in-class albumin tripartite of significant unmet need complex (ATC) activator in development for Wilson disease • Phase 3 piv

  4. Slide 4: Strong Management Team with a History of Success in Drug Development and Commercialization

    Strong Management Team with a History of Success in Drug Development and Commercialization Christopher Starr, PhD Chandler Robinson, MD, MBA, MSc Co-Founder, Exec Chairman Co-Founder, CEO • Co-Founder & Former CEO, • Co-Founder, Tactic Pharma and Raptor Pharma (Nasdaq: RPTP), Wilson Tx; lead drug AL

  5. Slide 5: ALXN1840: First-in-Class Albumin Tripartite Complex Activator

    ALXN1840 First-in-Class Albumin Tripartite Complex Activator 5 / ©2026 Monopar

  6. Slide 6: Wilson Disease: A Rare and Serious Genetic Disorder Requiring Life-long Treatment

    Wilson Disease: A Rare and Serious Genetic Disorder Requiring Life-long Treatment CLINICAL MANIFESTATIONS OF WILSON DISEASE5 Rare genetic disorder of impaired Neurologic / copper (Cu) transport1 Psychiatric: • Life-long condition that requires • tremor life-long treatment2 • dystonia • anxiety, depr

  7. Slide 7: 2026 EL-PFDD Meeting Brought the Patient Voice into Wilson Disease Drug Development

    2026 Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting Brought the Patient Voice into Wilson Disease Drug Development What patients and caregivers said: Virtual EL-PFDD Meeting Participants described hepatic, neurologic, and psychiatric effects of Wilson disease, as well as the Janua

  8. Slide 8: Patient Experiences Highlight the Profound Impact of Wilson Disease

    Patient Experiences Highlight the Profound Impact of Wilson Disease on Daily Function, Independence, and Quality of Life “Difficulty speaking has caused others to perceive me as “I had intention tremors, not able to mentally challenged and to feel sorry for me and not taking pick up a spoon and eat.

  9. Slide 9: Majority of Newly Diagnosed Patients Are Symptomatic Across Multiple Domains

    The Majority of Newly Diagnosed Patients Are Symptomatic, and Many Are Symptomatic Across Multiple Domains AFFECTED DOMAINS AT TIME OF DIAGNOSIS 1 90% 54% Patients with any Prevalence of liver symptoms at time cirrhosis at time of of diagnosis1 diagnosis among HEPATIC 70% biopsied patients2 NEUROLOG

  10. Slide 10: Symptoms Persist Despite Treatment with SOC, with High Discontinuation Rates

    Symptoms Persist Despite Treatment with SOC, with High Treatment Discontinuation Rates of patients discontinued 29% initial standard of care2 (median duration: 8.1 months) PREVALENCE OF SYMPTOMS AFTER 1 YEAR OF TREATMENT 1 TOP REASONS FOR DISCONTINUATION HEPATIC 38% Side effects / tolerability 41% N

  11. Slide 11: Currently Available Therapies Are Associated with Multiple Challenges

    Currently Available IN THEIR OWN WORDS4… Therapies Are Associated “In the year and a half that I was on trientine, my with Multiple Challenges symptoms worsened even further. So, it went from loss of balance to completely bedbound, could not move myself at all, slurred speech to completely • Limited

  12. Slide 12: ALXN1840 Dataset Characterizing Novel Mechanism, Safety, and Effectiveness

    ALXN1840 Dataset Characterizing Novel Mechanism, Safety, and Effectiveness Is Comprehensive Study Findings In Vitro and In Vivo • Confirmed high Cu affinity (~10,000x greater than penicillamine/trientine)1 Mechanistic Studies • Characterized protein-centered mechanism of Cu mobilization and sequestr

  13. Slide 13: ALXN1840: First-in-Class Albumin Tripartite Complex Activator

    ALXN1840: A First-in-Class Albumin Tripartite Complex (ATC) Activator, Advancing a New Mechanistic Approach in Wilson Disease A NOVEL, PROTEIN-CENTERED MECHANISM DESIGNED TO DETOXIFY COPPER BINDS SEQUESTERS EXCRETES Binds free and tissue copper with Tightly sequesters mobilized, drug- Facilitates co

  14. Slide 14: Mechanistic Studies Characterize Copper Sequestration and Elimination

    Mechanistic Studies Characterize Copper Sequestration and Elimination for ALXN1840 SEQUESTRATION ELIMINATION Mouse model of WD, brain copper concentration1 Phase 2**, open-label, single-arm copper balance study in 8 patients with WD2 Fecal Cu output: Cu balance: 10,000 Water +49% from baseline -6.08

  15. Slide 15: Phase 3 Pivotal Trial: Largest and Longest Prospective Study in Wilson Disease

    ALXN1840 Phase 3 Pivotal Trial Represents the Largest and Longest Prospective Study Conducted in Patients with Wilson Disease Multi-Center, Active-Controlled Study with 207 Adults & Adolescents with WD Aged ≥12 Years PHASE 3 TRIAL PHASE 3 OPEN-LABEL EXTENSION ALXN1840 Randomization Completed Continu

  16. Slide 16: Trial Met Primary Endpoint: Superior Copper Mobilization vs. SOC

    PHASE 3 + EXTENSION Trial Met Primary Endpoint: ALXN1840 Demonstrated Superior Copper Mobilization vs. SOC • Over 3x greater copper Copper Mobilization (Mean dNCC) by Treatment Arm, Primary + Extension mobilization as measured by dNCC AUEC over 48 weeks on ALXN1840 ALXN1840 compared to SOC 300 Stand

  17. Slide 17: Improvement in CGI-I with ALXN1840 vs. SOC

    PHASE 3 TRIAL Improvement in Clinical Global Impression – Improvement (CGI-I) with ALXN1840 vs. SOC Secondary Endpoint: Clinical Global Impression - Improvement (CGI-I) 0.2 Mean Transformed CGI-I ± 95% CI 0.0 NO CHANGE CGI-I Change from Baseline to IMPROVEMENT -0.2 Week 48, ALXN1840 vs. SOC -0.4 -0.

  18. Slide 18: Greater Neurologic Improvement and Less Worsening than SOC

    PHASE 3 TRIAL Patients on ALXN1840 with Neurologic Symptoms Experienced Greater Neurologic Improvement and Less Worsening than SOC; Neurologic Benefit of ALXN1840 Observed in Multiple Trials Phase 3 Pivotal Trial - Patients Neurologic Symptom Improvement Consistently with Neuro Symptoms (n=112*)1 De

  19. Slide 19: Durable Neurologic Improvement in Open-Label Extension Study

    PHASE 3 + EXTENSION Durable Neurologic Symptom Improvement Was Observed in the ALXN1840 Phase 3 Open-Label Extension Study Neurologic Measure - UWDRS Part III (rater-blinded through week 48) ALXN1840 6 Mean Change in UWDRS Part III ± 95% CI 3 BASELINE 117 ALXN1840 patients 0 IMPROVEMENT continued fr

  20. Slide 20: Patient Reported Outcomes Favored ALXN1840 Over SOC

    PHASE 3 + EXTENSION Patient Reported Outcomes Favored ALXN1840 Over SOC Treatment Satisfaction Questionnaire for Medication (TSQM-9) Treatment Effectiveness Treatment Convenience 85 90 ALXN1840 SOC 80 85 Crossover (SOC ALXN1840) 80 75 75 Score (0-100) Score (0-100) 70 70 65 65 60 60 Number of patien

  21. Slide 21: Safety and Tolerability Profile in Phase 3 Pivotal Trial

    PHASE 3 TRIAL Safety and Tolerability Profile in Phase 3 Pivotal Trial Adverse Events Occurring in ≥5% of Patients Treated with ALXN1840 Adverse Event ALXN1840 SOC (n=137) (n=70) Elevated ALT* 14.6% 2.9% • The most frequently occurring adverse event Nasopharyngitis 10.9% 17.1% in patients treated wi

  22. Slide 22: ALXN1840 Pooled Phase 2/3 Safety Data

    PHASE 2/3 TRIAL ALXN1840 Pooled Phase 2/3 Safety Data Adverse Events in Pooled Safety Dataset (Phase 2 and Phase 3) Number of patients 297 Total patient-years 793.0 yrs • Most adverse events were low grade, non-serious, and occurred within first 6 months Median treatment duration 2.6 yrs of treatmen

  23. Slide 23: ALXN1840: First-in-Class Investigational Therapy with Novel Mechanism

    ALXN1840: First-in-class albumin First-in-Class Investigational Therapy with tripartite complex (ATC) Novel Mechanism and Compelling Clinical activator designed to Profile Supports Strong Market Position detoxify copper in patients with Wilson disease • 10,000x greater affinity to copper • Superior

  24. Slide 24: Novel Mechanism and Clinical Profile Addressing Critical Unmet Needs in Wilson Disease

    ALXN1840: Novel Mechanism and Compelling Clinical Profile Supports Strong Market Position, Addressing Critical Unmet Needs in Wilson Disease CURRENT STATE TARGETED FUTURE STATE WITH ALXN1840 Limited innovation over last 30 years First-in-class albumin tripartite complex (ATC) activator that detoxifi

  25. Slide 25: ALXN1840 Commercialization

    ALXN1840 Commercialization 25 / ©2026 Monopar

  26. Slide 26: Wilson Disease Market Dynamics Point to Significant Opportunity for ALXN1840

    Wilson Disease Market Dynamics Point to Significant Opportunity for ALXN1840 MARKET DYNAMIC ALXN1840 OPPORTUNITY Market is ripe for disruption with a novel Limitations of SOC therapies mechanism of action (MOA) innovation to address unmet needs Many patients are symptomatic, Opportunity for early up

  27. Slide 27: Positioning and Messaging Centered on Novel Mechanism

    Positioning and Messaging Centered on Novel Mechanism Designed to Detoxify Copper and Improve Neurologic Symptoms Advancing the Treatment of Wilson Disease ü Superior Copper Mobilization vs. Standard of Care (3x More Copper Mobilization) ALXN1840 ü Novel Mechanism Designed to Minimize Risk of Novel

  28. Slide 28: Monopar Ramping Commercial Organization to Launch ALXN1840 Upon Approval

    Monopar Ramping Commercial Organization to Launch ALXN1840 Upon Approval MARKET SHAPING BRAND & CUSTOMER STRATEGY PATIENT ACCESS & EXPERIENCE LAUNCH EXECUTION Thought Leader Scientific Communication Payer Value Sales Force Sizing Engagement Platform Proposition/Engagement & Alignment Priority Accoun

  29. Slide 29: Strategies and Tactical Programs Across Commercial Continuum

    Strategies and Tactical Programs Targeted Across Commercial Continuum to Optimize Uptake of ALXN1840 THE DEMAND TO DISPENSE CONTINUUM CREATE DEMAND (Rx GENERATION) CONVERT Rx TO DISPENSE (Rx FILLED) Patient Ease of Prescribing Product Selection Process & Confidence HCP Patient Affordability Patient

  30. Slide 30: Attractive Near-term Market Opportunity with Potential for Expansion

    Attractive Near-term Market Opportunity with Potential for Expansion Actively Managed Subset Represents Near Term Favorable Payer Mix Supports Opportunity with Expanded Growth Potential Patient Affordability ~11K+ Patients with Wilson Disease in the US (1:30k)1 ~7K Diagnosed with WD2 Wilson Disease

  31. Slide 31: Commercial Opportunity Accessed with Coverage of 3,000 HCPs

    ALXN1840 Commercial Opportunity Can Be Accessed with Coverage of 3,000 HCPs, with 75% of the Opportunity Concentrated Across 2,000 HCPs ~3,000 HCPs TOTAL UNIVERSE ~150 ~910 ~2,040 HCPs manage HCPs manage HCPs manage 25% of patients 50% of patients 75% of patients 5% 25% 29% 50% 68% 75% of HCPs of Pa

  32. Slide 32: Establishing Market Presence Across Key Peer Review Forums and Publications

    Monopar Establishing Strong Market Presence with Presentation of Science and Data Across Key Peer Review Forums and Publications EASL Poster ANA Poster & EASL Oral Presentation Wilson (May 2026) Presentation Oral Presentation Disease “Tiomolibdate choline stabilizes liver disease and (May 2025) (Oct

  33. Slide 33: Monopar Preparing to Re-State Wilson Disease Market with Anticipated Launch

    • Wilson disease is a high clinical unmet need therapeutic area • ALXN1840 novel MOA, efficacy, and safety profile characterized by its comprehensive and robust clinical development program, supports a strong market position as a novel therapy to address the critical unmet needs in Wilson disease Mo

  34. Slide 34: MNPR-101: First-in-Class Radiolabeled Antibody Targeting uPAR

    MNPR-101 A First-in-Class Radiolabeled Antibody Targeting uPAR 34 / ©2026 Monopar

  35. Slide 35: MNPR-101: A First-in-Class Radiolabeled Antibody Targeting uPAR

    MNPR-101: A First-in-Class Radiolabeled Antibody Targeting uPAR Preclinical Pancreatic Cancer (MIA PaCa-2) • First-in-class humanized antibody Control (no treatment) MNPR-101-Lu (100 µCi) targeting uPAR* % of Initial Tumor Volume % Patients 2500 • uPAR expressed in aggressive tumors, with uPAR 2000

  36. Slide 36: Human Clinical Data Confirms MNPR-101's Tumor Targeting Ability

    Human Clinical Data Confirms MNPR-101’s Tumor Targeting Ability ¹⁸F-fluorodeoxyglucose (FDG) MNPR-101-Zr (72h) 10 10 72-year-old female metastatic ovarian cancer primary tumor resected 0 SUV FDG image acquired 14 days prior to MNPR-101-Zr administration on the same Siemens Biograph Vision Quadra PET

  37. Slide 37: Monopar Advancing ALXN1840 and Ramping for Commercial Launch

    Monopar Advancing ALXN1840 and Ramping for Commercial Launch Key Accomplishments Upcoming Milestones • Strategic Acquisition: Acquired ALXN1840, a late- • Regulatory: Complete rolling NDA submission. stage Wilson disease asset supported by Phase 3 FDA decision on acceptance of filing and PDUFA clini

  38. Slide 38: Thank You

    Thank You ©2026 Monopar

Monopar Therapeutics — Investor Presentation (November 2026) on 6ix